Menu
ncarol.com
  • Home
  • Business
  • Health
  • Entertainment
  • Arts
  • Education
  • Technology
  • Real Estate
  • Non-profit
ncarol.com

HCPs Anticipate Disruption of Oral T2D Landscape by Division
ncarol.com/10211391

Trending...
  • DuoKey to Unveil Encrypted Financial Intelligence Use Case at GISEC Global 2025
  • Sober.Buzz the Sober Token : Ticker $BUZZ
  • myb.day Launches New Birthday Gift Shop Filled With Personalized Surprises
RESEARCH TRIANGLE PARK, N.C. - ncarol.com -- A variety of factors are considered when healthcare providers (HCPs) speak upon which type 2 diabetes treatments in the clinical pipeline may be more disruptive and why. According to newly published data by market research from Vivisum Partners, LLC., new arrivals are likely to take some pieces of the current share of oral treatments on market, but it may be enough to cause some dents in multiple treatments due to viable alternatives.

The current market holds a lot of excitement for the oral type 2 diabetes pipeline for drugs that are just as comparable in tolerability, but may differ on other clinical attributes, such as dosing. The most potential risk for a more established treatment will be pipeline products gaining more access.

For example, according to Oral T2D Clinical Pipeline, many HCPs expect oral Insulin's efficacy to be slightly or much better than current oral T2D treatments. In dosing, oral Insulin is believed to be slightly better according to a significant percentage of endocrinologists. Familiarity with HCPs could represent much of the difference in access for patients.

More on ncarol.com
  • Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
  • Cybersecurity is Protecting Your Personal Information and Your Portfolio
  • Matthew Glova, CFP® of LifeTime Asset Honored in Forbes Best-In-State Wealth Advisors2025
  • L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
  • Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success

Despite significant excitement for physicians who are familiar with oral insulin there is significant excitement. There is an overall low level of familiarity with other oral T2D pipeline medications. Only 21% of HCPs are familiar with oral insulin, which is the highest percentage of familiarity among any clinical pipeline treatment.

Vivisum Partners surveyed Endocrinologists and HCPs about each oral type 2 diabetes pipeline therapy. The survey results specify their degree of excitement, "HCPs are evenly split between being excited (48%) vs. ambivalent (48%) towards Sotagliflozin", -said Vivisum's Oral Type 2 Diabetes strategist Patrick Brunell. He adds, this suggests that HCPs are interested in Sotagliflozin, but remain skeptical on how well it will perform in the market." Most Endocrinologists (80%) believe that Sotagliflozin will have about the same level of access as current diabetes medications.

Many of the metrics used in the report show that established treatments may have to get used to sharing larger portions of the Oral T2D marketplace. Relying on brand recognition may or may not be enough. Oral T2D Clinical Pipeline Analysis, https://vivisumpartners.com/reports/new-diabetes-medications-clinical-pipeline-analysis/, published in January 2023 by Vivisum Partners, examines each oral type 2 diabetes drug's strengths and weaknesses across six key clinical attributes:
  • Access
  • Dosing
  • Efficacy
  • Safety
  • Support
  • Tolerability

ABOUT VIVISUM PARTNERS, LLC

More on ncarol.com
  • Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
  • The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
  • $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
  • SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
  • New National Nonprofit Launches to Capture Firsthand Accounts of Adoption Stories

Vivisum Partners, LLC is a market research agency providing strategic consulting around marketing and brand building. Vivisum provides facilitated discovery using market research methodologies and critical thinking processes. The actionable market research insights that Vivisum provides enable clients to shape their commercial strategies.

Contact
Candice Smith
***@vivisumpartners.com


Source: Vivisum Partners, LLC

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Bonelli Systems Expands Managed IT Services Nationwide, Leveraging Microsoft Azure Expertise
  • $4.3 Million Patent Application Waiver Fee Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression & PTSD: NRX Pharma
  • Whistleblower Claims Dental Patient Deaths Likely Due to Book Ban
  • Dr. Michael Matzinger Honored with Silver Antelope Award for Distinguished Service to Youth
  • xREnergy up as much as +3,094,634% on first day listed on the XRP Ledger. Ticker : $XRE
  • Psychiatry's Legacy of Racism and Coercion Highlighted in Restraint Deaths
  • New Book 'Cybersecurity Leadership' Guides SME Leaders to Make Smart, Strategic Security Decisions
  • Longtime Durham Bulls Performer and Dog Trainer Hit Hard by Economic Shift
  • "Stop scrolling and start watching" - Beloved film recommendation site Criticker gets a major makeover
  • Green Energy Solar Expands with New Offices in Port St. Lucie, West Palm Beach, and Orlando
  • Introducing the Wackadoodles for Kids Music
  • Events by Dubsdread Expands Services to The Venue at Lake Lily
  • London Gala Emphasizes Trade, FDI and Ongoing Cooperation
  • Sahit Muja Launches Trillion-Dollar Green Revolution with 10 Groundbreaking Cryptos
  • Free and Low-Cost Dental Care Now Available in London Through the Canadian Dental Care Plan (CDCP)
  • Garden State Gay Socials Turns One: 1st Birthday Celebration for Gay Men Who Want Real Connection
  • Sea Fox® 368X "Extreme Edition" by Black Label Marine Group Celebrates 5 Years of the Commander Legacy
  • CCHR Florida: Mental Health Awareness Month Open House
  • Introducing LĪNA Universal Balm: A Luxury Multi-Use, Plant-Powered Solution for Skin & Hair
  • UIFCA Revolutionizes Financial Education with Elite Team of Investment Experts
_catLbl0 _catLbl1

Popular on ncarol.com

  • 11th annual Florida Blueberry Festival April 26 & 27, 2025 - 169
  • Village Vapes and Cooking 4 Autism Announce Inaugural Partnership at MEGA 420 EVENT - 161
  • Perfect Body Laser & Aesthetics Launches New Website - 119
  • New Blog Post Shares the Ultimate List of Free Resources to Help Artists Make a Comic - 105
  • The Ultimate Med Spa Growth Engine: PatientNow and Aesthetix CRM Announce Strategic Integration - 101
  • Rising Pop R&B Sensation Leon Zellers to Release New Single "Wanna Know" on April 11
  • North American Security Launches New Website to Reflect Evolving Industry Demands and Client-Centered Solutions
  • The World's No.1 Superstar Champions the NO FAKES Act – Secures Global Identity and Cultural Legacy
  • 19th Annual High Performance Home Tour Will Feature Green Certified Homes Throughout The Triangle
  • Artist Séfora Camazano Honored with Prestigious Prize "The New Great Masters in New York"

Similar on ncarol.com

  • 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
  • $4.3 Million Patent Application Waiver Fee Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression & PTSD: NRX Pharma
  • Meditech International Inc. and Los Angeles Rams Continue Strategic Partnership to Enhance Athlete Performance and Recovery
  • Mission 3A Establishes Healthcare Advisory Board with Addition of Industry Leaders Patrick Fisher, Kevin Cordell, and Dr. Greg Berlet
  • First Choice Neurology Partners with NeuroDiscovery AI to Advance Neurological Care and Research
  • $4.3 Million Waiver Exemption Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression, PTSD: NRx: Stock Symbol: NRXP
  • Clinical Endpoints Successfully Met in Study for Groundbreaking 12-Lead ECG Synthesis Technology Allowing Software Application to FDA: HeartBeam, Inc
  • Large Strategic Investment from Global Medical Device Manufacturer to Support Clinics Treating Suicidal Depression and PTSD: NRx: (Stock Symbol: NRXP)
  • $300 Million in Milestones; Double-Digit Royalties; Neurospa LOI for Expansion of International Psychiatry Clinics plus NDA Filed with FDA on New Drug
  • Dentaluxe's New Website Launch!
Copyright © 2025 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute